MARKETS / NYMXF
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · MID CAP
Nymox Pharmaceutical Corp. NYMXF
10 fiscal years on record · USD · FY2024 reported · SEC filings only
$-4.5M
$-2.6M
Growth
—
Revenue, FY2024 · full 10-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -8.8
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2020 · Operating -234400.0% · Net -234760.0%
ROE
Not available in our data for this period.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | −0.0 | · |
| EPS, diluted $ | −0.05 | −0.10 | −0.07 | −0.15 | −0.16 | −0.19 | · | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · |
| Shares out B | 0.09 | 0.09 | · | · | · | 0.07 | 0.06 | 0.06 | 0.05 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 36 reconciliationsAUDITED
Reconciled in 10 of 19 fiscal years. 50 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIn Vitro & In Vivo Diagnostic Substances
Listed onnot stated in the filings
Incorporated innot stated in the filings
Fiscal year endsDecember 31
Data on record since2015